000			02044 a2200601 4500
005			20250517202940.0
264		0	_c20190708
008			201907s 0 0 eng d
022			_a1538-8514
024	7		_a10.1158/1535-7163.MCT-17-0758 _2doi
040			_aNLM _beng _cNLM
100	1		_aFloc'h, Nicolas
245	0	0	_aAntitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. _h[electronic resource]
260			_bMolecular cancer therapeutics _c05 2018
300			_a885-896 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural
650	0	4	_aAcrylamides
650	0	4	_aAniline Compounds
650	0	4	_aAnimals
650	0	4	_aCOS Cells
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aCell Line, Tumor
650	0	4	_aChlorocebus aethiops
650	0	4	_aErbB Receptors _xantagonists & inhibitors
650	0	4	_aExons _xgenetics
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMice, SCID
650	0	4	_aMutation
650	0	4	_aPiperazines _xpharmacology
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aXenograft Model Antitumor Assays _xmethods
700	1		_aMartin, Matthew J
700	1		_aRiess, Jonathan W
700	1		_aOrme, Jonathan P
700	1		_aStaniszewska, Anna D
700	1		_aMénard, Ludovic
700	1		_aCuomo, Maria Emanuela
700	1		_aO'Neill, Daniel J
700	1		_aWard, Richard A
700	1		_aFinlay, M Raymond V
700	1		_aMcKerrecher, Darren
700	1		_aCheng, Mingshan
700	1		_aVang, Daniel P
700	1		_aBurich, Rebekah A
700	1		_aKeck, James G
700	1		_aGandara, David R
700	1		_aMack, Philip C
700	1		_aCross, Darren A E
773	0		_tMolecular cancer therapeutics _gvol. 17 _gno. 5 _gp. 885-896
856	4	0	_uhttps://doi.org/10.1158/1535-7163.MCT-17-0758 _zAvailable from publisher's website
999			_c28124859 _d28124859